Physician profile
Wonil Lee
NPI 1992780225
$26,255.96
in general payments reported to CMS, 2019-2025
48 companies · $3,621 in 2025
The $3,621 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,824 · 2020: $3,505 · 2021: $3,125 · 2022: $4,759 · 2023: $3,296 · 2024: $4,126 · 2025: $3,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $66.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,976.73 |
| Education | $66.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $8,961.70 | 2019-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $3,807.91 | 2019-2025 | |
| Janssen Biotech, INC. | $2,147.37 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $2,025.73 | 2019-2025 | |
| Pfizer INC. | $894.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $888.69 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $771.59 | 2019-2023 | Krystexxa |
| Pacira Therapeutics, INC. | $719.69 | 2019-2021 | |
| Genzyme Corporation | $693.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $676.63 | 2019-2025 | Benlysta |
| Ucb, INC. | $553.28 | 2019-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.84 | 2020-2025 | Ofev, Cyltezo, Jascayd |
| E.R. Squibb & Sons, L.L.C. | $410.24 | 2019-2022 | |
| Radius Health, INC. | $333.74 | 2020-2025 | Tymlos |
| Lilly USA, LLC | $285.76 | 2019-2021 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $231.47 | 2021-2025 | Hadlima, Renflexis, Nexplanon |
| Tersera Therapeutics LLC | $228.59 | 2022-2025 | Quzyttir |
| Ani Pharmaceuticals, INC. | $216.51 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $170.97 | 2020-2023 | Acthar |
| Merck Sharp & Dohme LLC | $170.21 | 2019-2020 | |
| Celgene Corporation | $162.34 | 2019 | |
| Aurinia Pharma U.S., INC. | $145.75 | 2021-2024 | Lupkynis |
| Fidia Pharma USA INC. | $127.94 | 2019-2022 | |
| Shockwave Medical, INC | $125.89 | 2025 | |
| Bioventus LLC | $112.78 | 2022-2023 | Durolane |
| Genentech USA, INC. | $102.53 | 2022-2025 | Actemra |
| Eisai INC. | $95.71 | 2020-2021 | |
| Sandoz INC. | $78.06 | 2023-2025 | Hyrimoz, Jubbonti |
| Alexion Pharmaceuticals, INC. | $74.10 | 2022-2025 | Strensiq, Ultomiris |
| Celltrion USA INC. | $65.85 | 2023 | Yuflyma |
| Fresenius Kabi USA, LLC | $65.75 | 2023 | |
| Stryker Corporation | $46.43 | 2022 | |
| Depuy Synthes Sales INC. | $39.56 | 2022 | |
| Oxford Immunotec USA INC | $38.13 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $36.14 | 2023-2024 | Truxima |
| Regeneron Healthcare Solutions, INC. | $33.08 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $29.46 | 2022 | |
| Invivyd INC | $26.96 | 2025 | Pemgarda |
| Kiniksa Pharmaceuticals, Ltd. | $26.74 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.30 | 2020 | |
| Mallinckrodt Enterprises LLC | $24.02 | 2019 | |
| Zimmer Biomet Holdings, INC. | $22.20 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Octapharma USA, INC. | $18.70 | 2023 | Octagam Immune Globulin (Human) |
| Sobi, INC | $18.62 | 2019 | |
| Tonix Medicines, INC. | $16.09 | 2025 | Tonmya |
| Eusa Pharma (US) LLC | $14.62 | 2020 | |
| Vertiflex, INC. | $14.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wonil Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.